| 人胰高血糖素样肽-1类似物的合理应用 |
| |
| 引用本文： | 朱大龙,杨文英.人胰高血糖素样肽-1类似物的合理应用[J].临床药物治疗杂志,2013,0(1):1-5,31. |
| |
| 作者姓名： | 朱大龙 杨文英 |
| |
| 作者单位： | 1. 南京大学鼓楼医院内分泌科 南京 210008
2. 卫生部中日友好医院内分泌科 北京 100029 |
| |
| 摘 要： | 传统2型糖尿病的治疗是在饮食、运动控制的基础上,使用多种口服药或者联合胰岛素治疗,本文着重介绍治疗成人2型糖尿病的新药人胰高血糖素样肽-1类似物利拉鲁肽在临床应用中的疗效及不良反应。大型LEAD系列研究以及在亚洲尤其是中国患者中展开的临床研究结果证实了利拉鲁肽具有葡萄糖依赖性降糖的特点,兼具有保护β细胞、降低体重、血压以及低血糖发生率低的优势,同时不良反应发生率低,为临床治疗2型糖尿病提供了新的治疗选择。
|
| 关 键 词： | 2型糖尿病 利拉鲁肽 低血糖 |
Application of Glucagon-like Peptide-1 Analogue |
| |
| Zhu Da-long,Yang Wen-ying.Application of Glucagon-like Peptide-1 Analogue[J].Clinical Medication JOurnal,2013,0(1):1-5,31. |
| |
| Authors: | Zhu Da-long Yang Wen-ying |
| |
| Institution: | 1 Endocrinology Department,Nanjing Drum Tower Hospital,The Affiliated Hospital of Nanjing University Medical School,Nanjing,210008;2 Endocrinology Department,China-Japan Friendship Hospital,Beijing 100029,China |
| |
| Abstract: | Conventional treatment of type 2 diabetes is to use multiple oral anti-hyperglycemic drugs and/or insulin based on the control of diet and physical activity.We emphasize the efficacy and safety of the new drug —Glucagon-like peptide-1 analogue（Liraglutide） in clinical trials of treating patients with type 2 diabetes.The results of large scale of LEAD series study,clinical study in Asian especially Chinese patients approve liraglutide＇s multiple beneficial.Liraglutide decreases blood glucose in glucose-dependent manner,protects β cell function,decreases body weight as well as reduces systolic blood pressure.Besides,the rates of hypoglycemic and other side effects are low,thus providing a better way to treat type 2 diabetes. |
| |
| Keywords: | type 2 diabetes liraglutide hypoglycemic |
| 本文献已被 CNKI 维普 万方数据 等数据库收录！ |
|
